Serum ischemia modified albumin levels in subclinical cushing's syndrome

Basit Öğe Kaydı
dc.contributor.authorOzkul, Faruk
dc.contributor.authorTurkon, Hakan
dc.contributor.authorCakir, Dilek Ulker
dc.contributor.authorEroglu, Mustafa
dc.contributor.authorTutunculer, Funda Kirtay
dc.contributor.authorFaydaci, Umut
dc.contributor.authorUkinç, Kubilay
dc.date.accessioned2025-01-27T18:58:56Z
dc.date.available2025-01-27T18:58:56Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Subclinical Cushing's syndrome (SCS) is defined as biochemical overt cortisol excess in the absence of the classical signs and symptoms of Cushing's disease. The prevalence of SCS is reported as between approximately 5% and 24% in patients with adrenal incidentalomas (AI). SCS has increased cardiovascular and metabolic risk factors, and metabolic syndrome. Recently some studies demonstrated oxidative stress enhancement in Cushing's disease. Ischemia-modified albumin (IMA) is a marker of ischemia and oxidative stress and is increased in different clinical conditions such as cardiovascular diseases and metabolic syndrome. However, it has not been investigated in the patients with SCS. We aimed to evaluate serum IMA levels in the patients with SCS. Materials and methods: A total of 128 patients with AI were included in this study (17 patients with SCS and 111 patients with non-functional adenomas (NFA)). All patients were evaluated for the presence of adrenal masses using adrenal computed tomography (CT) scans. Serum IMA levels were measured by using a colorimetric method. Results: Serum IMA levels were significantly higher in SCS patients than in NFA patients (p < 0.05). Serum IMA was significantly correlated with waist circumference, low-density lipoprotein (LDL) levels and SCS. Furthermore, regression analysis revealed that serum IMA levels are independent and positively associated only with SCS. Conclusion: We concluded that elevated serum IMA levels might be accepted as a useful marker in patients with SCS. In order to reveal the pathological role of IMA levels in patients with SCS more studies are required.
dc.identifier.doi10.19193/0393-6384_2016_2_71
dc.identifier.endpage467
dc.identifier.issn0393-6384
dc.identifier.issue2
dc.identifier.scopus2-s2.0-84994240205
dc.identifier.scopusqualityN/A
dc.identifier.startpage463
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2016_2_71
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13079
dc.identifier.volume32
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherA. CARBONE Editore
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectAdrenal incidentaloma; Ischemia-modified albumin; Oxidative stress; Subclinical Cushing's syndrome
dc.titleSerum ischemia modified albumin levels in subclinical cushing's syndrome
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu